Level Four Advisory Services’s TG Therapeutics TGTX Stock Holding History

Level Four Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,640	Closed	-$314K	–	851
2023 Q2	$314K	Sell	12,640 -10,031	-44%	-$259K	0.02%	610
2023 Q1	$341K	Buy	+22,671	New	+$344K	0.02%	556

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Level Four Advisory Services's TGTX Position: Q3 2023 in Review

Level Four Advisory Services sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 12,640 shares — an estimated $314K sold.

Level Four Advisory Services first reported a position in TGTX in Q1 2023 and held it in 2 quarters. The position peaked at $341K in Q1 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

Level Four Advisory Services reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
Level Four Advisory Services sold 12,640 TG Therapeutics shares in Q3 2023, an estimated $314K.
Level Four Advisory Services first reported a position in TG Therapeutics in Q1 2023 and held it in 2 quarters.
Level Four Advisory Services's TG Therapeutics position peaked at $341K in Q1 2023.
236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Level Four Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.